Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Free Cash Flow: 2011-2024

Historic Free Cash Flow for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$114.2 million.

  • Ptc Therapeutics' Free Cash Flow rose 10.02% to -$69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $705.2 million, marking a year-over-year increase of 478.59%. This contributed to the annual value of -$114.2 million for FY2024, which is 38.89% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Free Cash Flow of -$114.2 million as of FY2024, which was up 38.89% from -$186.9 million recorded in FY2023.
  • Ptc Therapeutics' 5-year Free Cash Flow high stood at -$114.2 million for FY2024, and its period low was -$388.7 million during FY2022.
  • Over the past 3 years, Ptc Therapeutics' median Free Cash Flow value was -$186.9 million (recorded in 2023), while the average stood at -$229.9 million.
  • In the last 5 years, Ptc Therapeutics' Free Cash Flow slumped by 88.54% in 2020 and then soared by 51.92% in 2023.
  • Ptc Therapeutics' Free Cash Flow (Yearly) stood at -$211.9 million in 2020, then tumbled by 31.91% to -$279.5 million in 2021, then tumbled by 39.04% to -$388.7 million in 2022, then surged by 51.92% to -$186.9 million in 2023, then surged by 38.89% to -$114.2 million in 2024.